Sort
10,766 grants matching “checkpoint inhibitor”
Targeting Protein Arginine Methyltransferases to Eradicate Acute Myeloid Leukemia
$708,057Ling Li · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
Population Modeling of Bladder Cancer Detection and Control
$707,395Thomas Trikalinos · Brown University · U01 · FY2021 · CA
Immunotherapy to deplete key Treg subsets in solid tumors
$706,495Peter David Suzdak · Sonoval Llc · R44 · FY2025 · CA
Role of Cdk9 in the Pathogenesis of Pulmonary Fibrosis
$705,334Dominik R Haudenschild · Methodist Hospital Research Institute · R01 · FY2025 · HL
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
$704,749David P Carbone · Ohio State University · R01 · FY2024 · CA
Leveraging fructose transport to create a privileged substrate to selectively fuel T cells
$704,431Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Mechanisms of cancer immunotherapy-associated thrombosis
$704,368Keith R. McCrae · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · HL
Understanding and targeting the DNA replication stress in cancer cells
$704,285Lee Zou · Massachusetts General Hospital · R35 · FY2021 · CA
Development and optimization of highly effective treatments in patients with head and neck cancer using in situ implantable microdevices
$703,540Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2025 · CA
Targeting Non Viral Markers of HIV Persistence
$703,510Timothy Jensen Henrich · University Of California, San Francisco · R01 · FY2020 · AI
New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma
$703,320Benjamin G. Neel · New York University School Of Medicine · R01 · FY2021 · CA
New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma
$703,320Benjamin G. Neel · New York University School Of Medicine · R01 · FY2025 · CA
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer
$703,176Benjamin G. Neel · New York University School Of Medicine · R01 · FY2021 · CA
Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer
$703,149Lorenzo Galluzzi · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma
$703,025Mark Yarchoan · Johns Hopkins University · R01 · FY2023 · CA
Targeting Non Viral Markers of HIV Persistence
$702,932Timothy Jensen Henrich · University Of California, San Francisco · R01 · FY2018 · AI
Validating the hybrid epithelial/mesenchymal state as a biomarker of treatment response and outcomes in head and neck cancer
$702,871Sidharth Venkata Puram · Washington University · U01 · FY2025 · DE
Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies
$702,748Taha Merghoub · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
$702,580John V. Heymach · University Of Tx Md Anderson Can Ctr · U01 · FY2020 · CA
Targeting Tumor-Associated Macrophages to Treat Lymphoma
$702,495Wendong Huang · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer
$702,059Benjamin G. Neel · New York University School Of Medicine · R01 · FY2025 · CA
A systems-level approach to therapeutically target STING in cancer
$701,876Ashley Marie Laughney · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Precision imaging of the spatial regulators of the hybrid epithelial/mesenchymal state in head and neck cancer
$701,699Shannon L Stott · Massachusetts General Hospital · R01 · FY2024 · DE
Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer
$701,661Priscilla Kaliopi Brastianos · Massachusetts General Hospital · R01 · FY2025 · CA
Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer
$701,408Priscilla Kaliopi Brastianos · Massachusetts General Hospital · R01 · FY2024 · CA